New hope for controlling stubborn hormonal high blood pressure
NCT ID NCT06381323
Summary
This study tested a new drug called finerenone for people with primary aldosteronism, a common cause of hard-to-treat high blood pressure. The research involved 55 patients to see if finerenone safely lowers blood pressure and protects the heart and kidneys better than current options. The goal was to provide a new treatment choice for patients who cannot have surgery or tolerate existing medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology, Drum Tower Hospital affiliated to Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
Conditions
Explore the condition pages connected to this study.